ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes... Show more
ATAI is expected to report earnings to fall 22.43% to -10 cents per share on November 18
Q3'25
Est.
$-0.11
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.09
Q3'24
Est.
$-0.16
The last earnings report on August 14 showed earnings per share of -14 cents, missing the estimate of -11 cents. With 1.50M shares outstanding, the current market capitalization sits at 1.30B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ATAI showed earnings on August 14, 2025. You can read more about the earnings report here.